AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on April 29, 2025.

By Elana Gotkine HealthDay Reporter

TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 25 to 30 in Chicago.

Yueshiu Lyu, M.D, from the Washington University School of Medicine in St. Louis, and colleagues examined trends in breast cancer IBM by race and molecular subtype (luminal A, luminal B, human epidermal growth factor receptor 2-enriched, and triple negative). Data were analyzed for 11,661 breast cancer deaths among women aged 20 to 49 years.

The researchers observed a decrease in IBM from 2010 to 2020, from 9.70 to 1.47/100,000 women. All subtypes and racial/ethnic groups had declines, with differences seen in the points of inflexion. For luminal A, IBM decreased consistently from 2010, followed by a more marked decline from 2017 (annual percent change [APC], −32.88). A similar pattern was seen for triple-negative breast cancer, with a marked decline in 2018 (APC, −32.82). In 2010 and 2020, the highest IBM was seen in non-Hispanic Black women (16.56 and 3.41/100,000, respectively) compared with non-Hispanic White women (9.18 and 1.16/100,000, respectively). In non-Hispanic Black women, declines in IBM became pronounced from 2016 (APC, −24.15), narrowing the gap with other racial groups. The worst survival was seen for non-Hispanic Black women, while non-Hispanic Whites and non-Hispanic Asian/Pacific Islanders had the best survival.

"We have made tremendous advances in reducing mortality from breast cancer in young women but there are still opportunities for improvements, especially in relation to eliminating disparities," coauthor Adetunji T. Toriola, M.D., Ph.D., M.P.H., also from Washington University, said in a statement.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-04-30 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords